PhRMA's Part D warnings echoed by AIDS Institute

US trade association PhRMA is concerned about proposed changes to the Medicare Part D program.

The pharma lobby group is opposing a proposed rule from the Centers of Medicare and Medicaid Services (CMS) – the Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses.

"These proposed changes would severely undermine patient access to drugs they need to survive"PhRMA claims that the policy would weaken access to the six protected classes of medicines, covering conditions including HIV, cancer and epilepsy, and has particular concerns around patients suffering from HIV/AIDS.